Skip NavigationSkip to Content
Return Return to Search Results

Translational considerations for cancer nanomedicine

  1. Author:
    Stern, S. T.
    Hall, J. B.
    Yu, L. L.
    Wood, L. J.
    Paciotti, G. F.
    Tamarkin, L.
    Long, S. E.
    McNeil, S. E.

  2. Author Address

    [Stern, Stephan T.; Hall, Jennifer B.; McNeil, Scott E.] NCI, Nanotechnol Characterizat Lab, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21702 USA. [Yu, Lee L.; Wood, Laura J.; Long, Stephen E.] NIST, Gaithersburg, MD 20899 USA. [Paciotti, Giulio F.; Tamarkin, Lawrence] CytImmune Sci, Rockville, MD 20850 USA.;Stern, ST, NCI, Nanotechnol Characterizat Lab, Adv Technol Program, SAIC Frederick Inc, POB B, Frederick, MD 21702 USA.;sternstephan@mail.nih.gov halljennifer@mail.nih.gov lee.yu@nist.gov laura.wood@nist.gov gpaciotti@cytimmune.com ltamarkin@cytimune.com stephen.long@nist.gov ncl@mail.nih.gov
    1. Year: 2010
    2. Date: Sep
  2. Journal: Journal of Controlled Release
    1. 146
    2. 2
    3. Pages: 164-174
  4. Type of Article: Proceedings Paper
  5. ISSN: 0168-3659
  1. Abstract:

    There are many important considerations during preclinical development of cancer nanomedicines, including: 1) unique aspects of animal study design; 2) the difficulties in evaluating biological potency, especially for complex formulations; 3) the importance of analytical methods that can determine platform stability in vivo, and differentiate bound and free active pharmaceutical ingredient (API) in biological matrices; and 4) the appropriateness of current dose scaling techniques for estimation of clinical first-in-man dose from preclinical data. Biologics share many commonalities with nanotechnology products with regard to complexity and biological attributes, and can, in some cases, provide context for dealing with these preclinical issues. In other instances, such as the case of in vivo stability analysis, new approaches are required. This paper will discuss the significance of these preclinical issues, and present examples of current methods and best practices for addressing them. Where possible, these recommendations are justified using the existing regulatory guidance literature. (C) 2010 Elsevier B.V. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.jconrel.2010.04.008
  3. View record in Web of Science®
  4. WOS: 000281261900002

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel